Egyptian Pharma Company to Produce 40 Million Doses of Sputnik V Vaccine

The Russian Direct Investment Fund (RDIF), the Egyptian pharmaceutical company Minapharm and its subsidiary, ProBioGen, announced an agreement to produce more than 40 million doses of the Sputnik V vaccine per year.

Beginning in the 3rd quarter of 2021, Sputnick V vaccine production is scheduled to launch at Minapharm's biotechnology facilities in Cairo, Egypt. ProBioGen, with expertise in vector technology, vaccine manufacturing, and gene therapy, will support streamlining production processes in the future.

Vafik Bardissi, Chairman and CEO of Minapharm, stated in a press release issued on April 22, 2021, “This agreement will strengthen Minapharm's regional leadership in biotechnology, which has been achieved through extensive international expertise in cell engineering and adenovirus vector technology."

"We are delighted to join RDIF in the fight against the coronavirus pandemic. ”

The Sputnik V vaccine uses two different vectors for two shots during the vaccination process, which creates stronger immunity than vaccines that use the same delivery mechanism for both shots. And the safety, efficacy, and lack of long-term negative effects of adenovirus vaccines have been proven in more than 250 clinical studies over two decades, says the RDIF.

Minapharm Pharmaceuticals is a leading pharmaceutical company with about 1,400 employees located in Africa, Egypt, and the Middle East. Minapharm sells over 100 products, from molecules to complex genetically engineered proteins. ProBioGen AG, a 100% subsidiary of Minapharm in Germany, is a globally renowned contract pharmaceutical company specializing in developing cell lines and supplying proprietary protein and viral vector technologies.